Cancer is a complex disease in which both genetic defects and microenvironmental
components contribute to the development, progression, and metastasization of disease …

Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults
associated with a poor survival. Current standard of care consists of surgical resection …

PARP inhibitors have been approved for the therapy of cancers with homologous
recombination (HR) deficiency based on the concept of “synthetic lethality”. However …

Glioblastoma (GBM) constitutes the most common primary brain tumor in adults. The
challenges in GBM therapeutics have shed light on zebrafish used as a promising animal …

Glioblastoma (GBM) is the most common and aggressive primary brain tumour, yet little
progress has been made towards providing better treatment options for patients diagnosed …

The future of improved immunotherapy against cancer depends on an in-depth
understanding of the dynamic interactions between the immune system and tumors. Over …

Photoactivatable molecules enable ablation of malignant cells under the control of light, yet
current agents can be ineffective at early stages of disease when target cells are similar to …

Triple negative breast cancer (TNBC) is known for being very aggressive, heterogeneous
and highly metastatic. The standard of care treatment is still chemotherapy, with adjacent …

Simple Summary Glioblastoma (GBM) is one of the greatest challenges facing neuro-
oncology today. Current treatments are far from satisfactory and, given the poor prognosis of …

Glioblastoma (GB) is a rare but extremely aggressive brain tumor that significantly impacts
patient outcomes, affecting both duration and quality of life. The protocol established by …